» Articles » PMID: 2401124

Pharmacokinetic Studies in Humans with the Oral Iron Chelator 1,2-dimethyl-3-hydroxypyrid-4-one

Overview
Publisher Wiley
Specialty Pharmacology
Date 1990 Sep 1
PMID 2401124
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacokinetic studies have been carried out with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). HPLC analysis of serum of a normal volunteer and seven transfusional iron loaded patients who ingested a 3 gm dose of L1 revealed that L1 was most probably absorbed from the stomach and was transferred to the blood with a half-life of 0.7 to 32 minutes. L1 reached maximum concentration in the serum 12 to 120 minutes after administration with 85% to 90% elimination within the first 5 to 6 hours, with a half-life of 47 to 134 minutes. L1 and its glucuronide metabolite were identified in serum and urine but not in feces. In most cases hydrolysis of 24-hour urine samples with use of beta-glucuronidase resulted in almost complete recovery of the administered dose. Urinary iron excretion was proportional to the iron load but not to the serum or urine concentration of L1. The therapeutic efficiency of L1 can therefore be improved by repeated administration of 2 to 3 gm doses at least every 6 hours.

Citing Articles

New Insights into Aspirin's Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites.

Kontoghiorghes G Antioxidants (Basel). 2025; 14(1).

PMID: 39857363 PMC: 11763074. DOI: 10.3390/antiox14010029.


The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites.

Kontoghiorghes G Int J Mol Sci. 2024; 25(10).

PMID: 38791185 PMC: 11121054. DOI: 10.3390/ijms25105150.


Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.

Kontoghiorghes G Int J Mol Sci. 2023; 24(23).

PMID: 38069073 PMC: 10706143. DOI: 10.3390/ijms242316749.


The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.

Kontoghiorghes G Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513928 PMC: 10384919. DOI: 10.3390/ph16071016.


Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.

Kontoghiorghes G Int J Mol Sci. 2023; 24(5).

PMID: 36902402 PMC: 10002863. DOI: 10.3390/ijms24054970.